Laura M. G. Meems

Laura M. G. Meems

Auto-generated profile, based on publicly available information

Laura M. G. Meems

Department of Cardiology, University Medical Centre Groningen , Groningen

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
CWCoenraad Withaar
Coenraad Withaar
LMLaura M G Meems
Laura M G Meems
GMGeorge Markousis-Mavrogenis
George Markousis-Mavrogenis
CBCornelis J Boogerd
Cornelis J Boogerd
HSHerman Silljé
Herman Silljé
RBRudolf A. De Boer
Rudolf A. De Boer
Aims: Heart failure with preserved ejection fraction (HFpEF) is a multifactorial disease that constitutes several distinct phenotypes, including a common cardiometabolic phenotype with obesity and type 2 diabetes mellitus. Treatment options for HFpEF are limited, and development of novel therapeutics is hindered by the paucity of suitable preclinical HFpEF models that recapitulate the complexity of human HFpEF. Metabolic drugs, like glucagon-like peptide receptor agonist (GLP-1 RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), have emerged as promising drugs to restore metabolic perturbations and may have value in the treatment of the cardiometabolic HFpEF phenotype. We aimed to develop a multifactorial HFpEF mouse model that closely resembles the cardiometabolic HFpEF phenotype, and evaluated the GLP-1 RA liraglutide (Lira) and the SGLT2i dapagliflozin (Dapa).Methods and results: Aged (18–22 months old) female C57BL/6J mice were fed a standardized chow (CTRL) or high-fat diet (HFD) for 12 weeks. After 8 weeks HFD, angiotensin II (ANGII), was administered for 4 weeks via osmotic mini pumps. HFD + ANGII resulted in a cardiometabolic HFpEF phenotype, including obesity, impaired glucose handling, and metabolic dysregulation with inflammation. The multiple hit resulted in typical clinical HFpEF features, including cardiac hypertrophy and fibrosis with preserved fractional shortening but with impaired myocardial deformation, atrial enlargement, lung congestion, and elevated blood pressures. Treatment with Lira attenuated the cardiometabolic dysregulation and improved cardiac function, with reduced cardiac hypertrophy, less myocardial fibrosis, and attenuation of atrial weight, natriuretic peptide levels, and lung congestion. Dapa treatment improved glucose handling, but had mild effects on the HFpEF phenotype.Conclusions: We developed a mouse model that recapitulates the human HFpEF disease, providing a novel opportunity to study disease pathogenesis and the development of enhanced therapeutic approaches. We furthermore show that attenuation of cardiometabolic dysregulation may represent a novel therapeutic target for the treatment of HFpEF.

20 August 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CWCoenraad Withaar
Coenraad Withaar
CLCarolyn S P Lam
Carolyn S P Lam
GSGabriele G Schiattarella
Gabriele G Schiattarella
RBRudolf A. De Boer
Rudolf A. De Boer
LMLaura M G Meems
Laura M G Meems
Heart failure (HF) with preserved ejection fraction (HFpEF) is a multifactorial disease accounting for a large and increasing proportion of all clinical HF presentations. As a clinical syndrome, HFpEF is characterized by typical signs and symptoms of HF, a distinct cardiac phenotype and raised natriuretic peptides. Non-cardiac comorbidities frequently co-exist and contribute to the pathophysiology of HFpEF. To date, no therapy has proven to improve outcomes in HFpEF, with drug development hampered, at least partly, by lack of consensus on appropriate standards for pre-clinical HFpEF models. Recently, two clinical algorithms (HFA-PEFF and H2FPEF scores) have been developed to improve and standardize the diagnosis of HFpEF. In this review, we evaluate the translational utility of HFpEF mouse models in the context of these HFpEF scores. We systematically recorded evidence of symptoms and signs of HF or clinical HFpEF features and included several cardiac and extra-cardiac parameters as well as age and sex for each HFpEF mouse model. We found that most of the pre-clinical HFpEF models do not meet the HFpEF clinical criteria, although some multifactorial models resemble human HFpEF to a reasonable extent. We therefore conclude that to optimize the translational value of mouse models to human HFpEF, a novel approach for the development of pre-clinical HFpEF models is needed, taking into account the complex HFpEF pathophysiology in humans.

14 October 2024 in JACC
Verified
Journal Article
Closed access
JDJust Dronkers
Just Dronkers
DVDirk J. van Veldhuisen
Dirk J. van Veldhuisen
PMPeter van der Meer
Peter van der Meer
LMLaura M.G. Meems
Laura M.G. Meems

30 November 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SLSunhuo Li
Sunhuo Li
CWCoenraad Withaar
Coenraad Withaar
PRPatricia G. Rodrigues
Patricia G. Rodrigues
SZSietske N. Zijlstra
Sietske N. Zijlstra
RBRudolf A. de Boer
Rudolf A. de Boer
LMLaura M.G. Meems
Laura M.G. Meems
Heart failure with preserved ejection fraction (HFpEF) is posing a significant medical challenge due to its growing prevalence, high hospitalization rates and limited response to current treatment options. Accumulating evidence suggests that a comorbidity-driven systemic pro-inflammatory state, including activation of the NLRP3 inflammasome, contributes to the pathogenesis of HFpEF. This study aimed to investigate the potential cardiac protective effects of the selective NLRP3 inhibitor MCC950, in a mouse model of HFpEF. HFpEF was obtained in 18-22 months old female mice using high-fat diet (HFD) and angiotensin II (AngII) infusion. Mice developed HFpEF and comorbidities such as obesity, type 2 diabetes, and hypertension. MCC950 was added to HFD and groups were treated for four weeks until the study endpoint. MCC950 treatment resulted in lower plasma IL-18 levels (-47.3 %), illustrating target engagement. First, we observed that MCC950 treatment improved left ventricular function, demonstrated by enhanced global longitudinal strain (GLS, 3.9 %, P<0.01) and reverse peak longitudinal strain (RPLSR, +46.8 %, P<0.05). Second, MCC950 reduced cardiac hypertrophy (cardiomyocyte size -19.5 %, P<0.001) and fibrosis (-32.5 %, P<0.05), accompanied by lower expression of pro-fibrotic genes. Finally, MCC950 treatment reduced macrophage infiltration in left ventricular tissue and attenuated macrophage accumulation in visceral adipose tissue, even more as compared to caloric restriction. Overall, this suggests that NLRP3 inhibition could be a promising treatment for HFpEF patients with a pro-inflammatory profile, potentially improving heart function, systemic inflammation, and metabolic parameters.

14 January 2021 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
Navin Suthahar MD, MSc, PhD, FESC, FHFANavin Suthahar MD, MSc, PhD, FESC, FHFA
Navin Suthahar MD, MSc, PhD, FESC, FHFA
LMLaura M.G. Meems
Laura M.G. Meems
DGDion Groothof
Dion Groothof
SBStephan Bakker
Stephan Bakker
RGRon T. Gansevoort
Ron T. Gansevoort
RBRudolf A. De Boer
Rudolf A. De Boer
Aims: There are limited data examining whether body mass index (BMI) influences the association between cardiovascular biomarkers and incident heart failure (HF). Methods and results: Thirteen biomarkers representing key HF domains were measured: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), mid‐regional pro‐A‐type natriuretic peptide (MR‐proANP), cardiac troponin T (cTnT), C‐reactive protein, procalcitonin, galectin‐3, C‐terminal pro‐endothelin‐1 (CT‐proET‐1), mid‐regional pro‐adrenomedullin, plasminogen activator inhibitor‐1, copeptin, renin, aldosterone, and cystatin‐C. Associations of biomarkers with BMI were examined using linear regression models, and with incident HF using Cox regression models. We selected biomarkers significantly associated with incident HF, and evaluated whether BMI modified these associations. Among 8202 individuals, 41% were overweight (BMI 25–30 kg/m 2 ), and 16% were obese (BMI ≥30 kg/m 2 ). Mean age of the cohort was 49 years (range 28–75), and 50% were women. All biomarkers except renin were associated with BMI: inverse associations were observed with NT‐proBNP, MR‐proANP, CT‐proET‐1 and aldosterone whereas positive associations were observed with the remaining biomarkers (all P ≤ 0.001). During 11.3 ± 3.1 years of follow‐up, 357 HF events were recorded. Only NT‐proBNP, MR‐proANP and cTnT remained associated with incident HF ( P < 0.001), and a significant biomarker*BMI interaction was not observed (interaction P > 0.1). Combined NT‐proBNP and cTnT measurements modestly improved performance metrics of the clinical HF model in overweight (ΔC‐statistic = 0.024; likelihood ratio χ 2 = 38; P < 0.001) and obese (ΔC‐statistic = 0.020; likelihood ratio χ 2 = 32; P < 0.001) individuals. Conclusions: Plasma concentrations of several cardiovascular biomarkers are influenced by obesity. Only NT‐proBNP, MR‐proANP and cTnT were associated with incident HF, and BMI did not modify these associations. A combination of NT‐proBNP and cTnT improves HF risk prediction in overweight and obese individuals.

1 April 2019 in Hypertension
Verified
Journal Article
Closed access
PDF file
LMLaura M.G. Meems
Laura M.G. Meems
IAIngrid A. Andersen
Ingrid A. Andersen
SPShuchong Pan
Shuchong Pan
GHGail Harty
Gail Harty
YCYang Chen
Yang Chen
JBJohn C. Burnett
John C. Burnett
Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1–7 (angiotensin 1–7)—the 7-amino acid endogenous activator of MasR. We assessed NPA7’s dual receptor activating actions in vitro (second messenger p...